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Combination therapyDiabetes is a leading cause of macrovascular and microvascular complications that can increase the risk of
mortality if not properly managed. Proper glucose control can reduce the incidence of these complications, in
particular those of the microvasculature. Over the last ~ 10 years, the cardiovascular safety of glucose-lowering
drugs has come to the forefront of diabetes management and clinical trial design. While early combination
therapy improves glycemic control, its impact on long-term outcomes, is not as clearly understood. The objective
of this review is to examine the evidence of early combination therapy for the treatment of type 2 diabetes
mellitus as it relates to studies of long-term microvascular and macrovascular outcomes.
© 2016 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Diabetes is a leading cause of death, cardiovascular disease (CVD),
and microvascular complications among U.S. adults (CDC, 2014b).
Although rates of myocardial infarction (MI) and stroke have declined
in the last two decades (Gregg et al., 2014), CVD death rates in 2003–
2006 were 1.7 times higher among adults with versus without
diabetes (CDC, 2014b). Similarly, the incidence of end-stage renal
disease (ESRD) related to diabetes decreased from 1995–2008 (CDC,
2014a), however, 44% of all new cases of kidney failure in the U.S. in
2011 listed diabetes as the primary cause.
Algorithms for the management of patients with type 2 diabetes
mellitus (T2DM) focus on treatment of hyperglycemia, and continue
to evolve as new evidence emerges on microvascular and macro-
vascular complications. In addition, recommendations were issued in
2008 by the U.S. Food and Drug Administration (FDA) to ensure that
new glucose-lowering agents do not exceed pre-speciﬁed CV risk
limits (upper bound of the 2-sided 95% conﬁdence interval [CI] for the
estimated risk ratio b1.3) (U.S. Department of Health and Human
Services, Food and Drug Administration, & Center for Drug Evaluation
and Research (CDER), 2008). The relationship between glucose levels
and vascular risk factors has been established in several prospectiveEast, Suite 200, Englewood, CO
301.
c. This is an open access article unand observational studies (Barr et al., 2007; Juutilainen, Lehto,
Rönnemaa, Pyörälä, & Laakso, 2008; Sarwar et al., 2010; Stratton
et al., 2000). In one study, pre-diabetes (glycated hemoglobin [HbA1c]
5.7%–6.4%) and T2DM were associated with an increased relative risk
(RR) for incident levels of elevated cardiac troponin, a measure of
subclinical myocardial damage (Selvin et al., 2014), suggesting that
hyperglycemia negatively impacts the myocardium before the
diagnosis of T2DM. Similarly, diabetic retinopathy can develop as
early as 7 years before diagnosis of T2DM (Fong, Aiello, Ferris, & Klein,
2004), and microalbuminuria has been identiﬁed in up to 7% of
patients with T2DM at the time of diagnosis (Adler et al., 2003).
1.1. Initiation and management of T2DM treatment
The American Diabetes Association (ADA)/European Association
for the Study of Diabetes (EASD) (Inzucchi et al., 2015) and the
American Association of Clinical Endocrinologists (AACE) (Garber
et al., 2016) recommend an HbA1c level of b7.0% and ≤6.5%,
respectively, for reducing the risk of diabetic complications in most
patients. Metformin has been a ﬁrst-line treatment for T2DM since it
was shown to decrease all-cause mortality compared with diet alone
in the United Kingdom Prospective Diabetes Study (UKPDS) (UKPDS
Group, 1998), and is considered the optimal drug for monotherapy
because of its “low cost, proven safety record, weight neutrality, and
possible beneﬁts on cardiovascular outcomes” (Inzucchi et al., 2015).
Both ADA/EASD and AACE algorithms outline a stepwise progression
from lifestyle changes, to monotherapy, and to combination therapyder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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glycemia. However, recommendations for add-on therapy choices and
the prerequisite for initiating dual therapy differ between algorithms.
Initial combination therapy is suggested for HbA1c levels ≥7.5%
(AACE) and ≥9% (ADA/EASD). Because of the progressive nature of
T2DM, many patients will need to intensify therapy to achieve
glycemic control (UKPDS Group, 1995).
The rationale for early therapy has been demonstrated in a pooled
analysis of patients with pre-diabetes, where assessments of insulin
secretion and insulin resistance showed that subjects in the upper
tertile of normal glucose tolerance had lost two-thirds of their β-cell
function, whereas those in the upper tertile of impaired glucose
tolerance (IGT), had lost 80%–85% (Defronzo, 2009). Thus, by the time
a diagnosis of T2DM was made, the majority of β-cell function was
lost. These key ﬁndings emphasize the need for early intervention in
the treatment of T2DM.
2. Objective and methods
This review examines the evidence of early combination therapy
for the treatment of T2DM as it relates to long-termmicrovascular and
macrovascular outcomes. Despite signiﬁcant advances in pharmaco-
logic approaches to treat hyperglycemia, the timing of combination
therapy and its impact on the prevention of long-term outcomes
requires further investigation.
A search of PubMed (through to March 2015) for clinical trials
evaluating combination glucose-lowering agents and long-term
outcomes for the treatment of T2DM was conducted. Search terms
included “type 2 diabetes macrovascular outcomes trial” or “type 2
diabetes MACE” (major adverse cardiac events) or “type 2 diabetes
microvascular outcomes trial.” The results were reviewed qualita-
tively based on treatment initiation time, duration of T2DM diagnosis,
and use of monotherapy, combination therapy, or multifactorial
therapy. The U.S. National Institutes of Health database of clinical
trials (ClincalTrials.gov) was used to search for ongoing trials of
combination glucose-lowering agents and long-term outcomes.
Updates to several clinical trials subsequently published, including
the cardiovascular (CV) outcome trial with empagliﬂozin, are
included. Because a limited number of studies have evaluated
long-term outcomes with early combination T2DM therapy, evidence
for intensive versus conventional glycemic control strategies and
combination therapy in patients with long-standing T2DM are
included in this narrative review.
3. The past: what have we learned from outcomes trials of intensive
versus conventional and combination glucose-lowering therapy?
3.1. Intensive versus conventional glycemic therapy in patients with
long-standing T2DM
Landmark outcomes trials – the Action to Control Cardiovascular
Risk in Diabetes (ACCORD) (Gerstein et al., 2008, 2011); Action in
Diabetes and Vascular Disease: Preterax and DiamicronMR Controlled
Evaluation (ADVANCE) (Patel et al., 2008; Zoungas et al., 2014); and
the Veterans Affairs Diabetes Trial (VADT) (Duckworth et al., 2009;
Hayward et al., 2015) – assessed the effect of intensive glucose
lowering on CV risk in patients with long-standing diabetes. These
trials were not designed to evaluate the effects of individual agents or
combination treatment on macrovascular outcomes; however, com-
binations of glucose-lowering drugs (intensive and standard therapy)
were utilized in an attempt to achieve glycemic targets (mean HbA1c
6.3%–6.9% for intensive therapy). The ACCORD trial was discontinued
prematurely because of an increased risk of all-cause mortality
(hazard ratio [HR], 1.22 [95% CI 1.01, 1.46]; P = 0.04) in the intensive
versus standard-therapy arm (Gerstein et al., 2008). In an additional
5-year follow-up exploratory analysis of intensive therapy, there wasa reduced risk for the combined endpoint of MI, coronary revascu-
larization, and unstable angina [overall HR 0.87 (95% CI 0.79, 0.96);
P = 0.006] (Gerstein et al., 2014); however, this beneﬁt was offset by
the earlier increased CV mortality risk (Gerstein et al., 2008). The
initial results of ADVANCE (Patel et al., 2008) and VADT (Duckworth
et al., 2009) also failed to demonstrate a signiﬁcant beneﬁt of
intensive glycemic control on macrovascular outcomes, although
intensive glycemic control improved microvascular outcomes in
ADVANCE (Patel et al., 2008) and slowed the progression of
albuminuria in VADT (Duckworth et al., 2009). In a 6-year, post-trial
follow-up of ADVANCE, tight glucose control resulted in signiﬁcant
improvements in ESRD (HR 0.54 [95% CI 0.34, 0.85]; P = 0.007).
However, no improvements in the composite for CV death, MI, or
stroke (HR 1.00 [95% CI 0.92, 1.08]; P = 0.93) or CV mortality (HR
0.97 [95% CI 0.86, 1.10]; P = 0.63) were observed (Zoungas et al.,
2014). The ~10-year follow-up to VADT showed that intensive
therapy reduced the risk of the primary composite CV outcome of
MI, stroke, new or worsening congestive heart failure (HF), death
from CV causes, or amputation (ischemic gangrene) (HR 0.83 [95% CI
0.70, 0.99]; P = 0.04). It did not show any difference in CV-related
mortality (HR 1.05 [95% CI 0.89, 1.25]; P = 0.54) (Hayward et al.,
2015). Taken together, these studies suggest that the CV beneﬁts of
intensive glucose-lowering therapymay be slow tomanifest, and may
also depend on individual patient characteristics such as short
duration of diagnosis, lower baseline HbA1c prior to intensive therapy,
and lack of concomitant CVD (Duckworth et al., 2011; Gerstein et al.,
2008; Skyler et al., 2009).
3.2. Combination therapy in patients with long-standing T2DM
The Rosiglitazone Evaluated for Cardiovascular Outcomes in oRal
agent combination therapy for type 2 Diabetes (RECORD) (Home
et al., 2009) and PROspective PioglitAzone Clinical Trial In macro-
Vascular Events (PROactive) (Dormandy et al., 2005) studies assessed
the effect of thiazolidinedione (TZD) add-on therapy onmicrovascular
and macrovascular outcomes in patients with a T2DM duration of 6–
10 years. In RECORD, addition of rosiglitazone to metformin or
sulfonylurea (SU) increased the rate of HF (HR 2.10 [95% CI 1.35, 3.27];
P = 0.0010) andwas inconclusive aboutMI risk (HR 1.14 [95% CI 0.80,
1.63]; P = 0.47) and CV mortality (HR 0.84 [95% CI 0.59, 1.18]; P =
0.32) (Home et al., 2009). The Bypass Angioplasty Revascularization
Investigation 2 Diabetes (BARI 2D) study showed similar rates of
ischemic CV events and congestive HF in patients with T2DM and
coronary artery disease with rosiglitazone versus patients not
receiving a TZD during 4.5 years of follow-up (Bach et al., 2013). In
patients with T2DM and a history of macrovascular disease in the
PROactive study, addition of pioglitazone to current diabetes and CV
medications did not signiﬁcantly reduce the time to the primary
composite endpoint. This primary composite endpoint included death
from any cause, nonfatal MI, stroke, acute coronary syndrome (ACS),
leg amputation, coronary revascularization, or revascularization of the
leg (HR 0.90 [95% CI 0.80, 1.02]; P = 0.095]. However, addition of
pioglitazone reduced the risk of the composite secondary endpoint
(death from any cause, nonfatal MI or nonfatal stroke (HR 0.84 [95% CI
0.72 to 0.98]; P = 0.027) (Dormandy et al., 2005).
Bromocriptinemesylate is a quick-release (QR) dopamine receptor
agonist that reduces glucose slightly without a risk of hypoglycemia
(Garber et al., 2016). In a placebo-controlled, randomized, 1-year
safety trial, patients (n = 3070) had an average baseline HbA1c of
7.0%, a mean T2DM duration of 8 years, and most were receiving
background therapy with additional oral agents or insulin. Compared
with placebo plus usual care, treatment with bromocriptine QR
signiﬁcantly reduced the composite CV endpoint of MI, stroke,
hospitalization for unstable angina, congestive HF, or revasculariza-
tion surgery (HR 0.60 [95% CI 0.35, 0.96]) (Gaziano et al., 2010). A post
hoc analysis that included CV mortality in the composite also showed
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restricted the composite to MACE (CV mortality, MI, and stroke [HR
0.48; 95% CI 0.23, 1.00]) (Gaziano et al., 2012).
In summary, the PROactive trial and the bromocriptine safety trial
suggest that pioglitazone and bromocriptine QR, respectively, may
reduce CV event rates, but these analyses did not have the full rigor of
a prospective cardiovascular outcomes study.
3.3. Early glucose-lowering and intensive therapy
Evidence for long-term outcomes with early glucose-lowering
combination therapy is limited. The landmark UKPDS randomized
newly diagnosed patients with T2DM to intensive or conventional
therapy (UKPDS Group, 1998). After a median 10 years, the intensive
arm had a signiﬁcantly lower risk for any diabetes-related endpoint (RR,
0.88; P = 0.029), most of which was due to a 25% risk reduction in
microvascular endpoints (RR, 0.75; P = 0.099). However, macrovascu-
lar endpoints, such as diabetes-related deaths (RR, 0.9; P = 0.34),
all-cause mortality (RR, 0.94; P = 0.44), or MI (RR, 0.84; P = 0.052)
were not signiﬁcantly reduced versus standard therapy (UKPDS Group,
1998). The CV beneﬁts of intensive glucose control, including a
signiﬁcant reduction in MI (15%; P = 0.01) and death from any cause
(13%; P = 0.007), became evident only after an additional 10 years post
trial and was subsequently termed the “legacy effect” (Holman, Paul,
Bethel,Matthews,&Neil, 2008). Theﬁndings suggest that early intensive
glucose-lowering therapy may offer long-term protection from CV
events; however, these changes may take a long time to manifest.
The Outcome Reduction with an Initial Glargine Intervention
(ORIGIN) trial included patients with prior CVD or at high risk of a CV
event, and impaired fasting glucose (IFG), IGT, or newly diagnosed or
established T2DM (mean duration ~5 years); baseline median HbA1c
was 6.4%. Patients received insulin glargine or standard therapy alone
for a median of 6.2 years. Results showed no signiﬁcant reduction in
the composite co-primary endpoint of CV death, nonfatal MI, and
nonfatal stroke. However, insulin glargine reduced incident diabetes
in patients with IFG and IGT (Gerstein et al., 2012).
Taken together, the difference in outcomes between UKPDS and
ORIGIN may relate to the patient populations and timing of the
intervention. Whereas ORIGIN included a mixed population with
pre-diabetes, early disease, or established T2DM; older age (mean
63.5 years); and established CVD or high CV risk, the UKPDS population
was younger (median 54 years) with newly diagnosed disease and
lower CV risk. Results from the Study TO Prevent Non-insulin-
Dependent Diabetes Mellitus (STOP–NIDDM), although not a trial of
intensive glucose control involving combinations of therapies in T2DM,
further support the importance of early intervention (Chiasson et al.,
2002). This trial evaluated the effect of acarbose 100 mg three times
daily versus placebo in preventing progression from IGT to T2DM, as
assessed by a yearly postprandial oral glucose tolerance test. Among the
analyzed population (mean age 54 years; n = 1368), acarbose delayed
the progression from IGT to T2DMover 3.3 years by 25% (Chiasson et al.,
2002). The study was not powered to examine CV outcomes but
analyzed the composite of coronary heart disease, CV death, congestive
HF, cerebrovascular events, and peripheral vascular disease as a
secondary endpoint. Based upon a small number of patients with
composite CV outcome events (acarbose, n = 15; placebo, n = 32), a
reduced risk of CV events was shown (HR, 0.51 [95% CI 0.28, 0.95]; P =
0.03) (Chiasson et al., 2003).
4. The present: recent evidence of improvements in clinical
outcomes with combination therapy
4.1. Initial combination therapy and glycemic control
A meta-analysis of 15 randomized controlled trials (N = 6693)
assessed whether initial combination therapy with metformin plusanother agent (TZD, sulfonylureas/glinides, dipeptidyl peptidase-4
[DPP-4] inhibitors or sodium glucose cotransporter 2 [SGLT2]
inhibitors) improved glycemic control in treatment-naïve patients
with T2DM (mean diabetes duration, 1.6–4.1 years; baseline mean
HbA1c, 7.2%–9.9%). When compared with metformin monotherapy,
combination treatment reduced HbA1c (weighted mean difference,
−0.43% [95% CI−0.56,−0.30]) but increased the risk of hypoglycemia
(RR, 1.56 [95% CI 1.08, 2.26]) (Phung, Sobieraj, Engel, & Rajpathak,
2014). Table 1 summarizes results for the newer glucose-lowering
therapies versus metformin included in the meta-analysis.
Since then, another study has demonstrated the efﬁcacy of
canagliﬂozin 100 mg and 300 mg in combination with metformin in
signiﬁcantly reducing HbA1c versus metformin in treatment-naïve
patients with T2DM (Rosenstock et al., 2016) (Table 1). Other recent
studies have evaluated the efﬁcacy of initial combination therapies with
DPP-4 inhibitors. For example, initial combination of linagliptin and
metformin in patientswith T2DMwas assessed in a 24-week trial (Haak
et al., 2012), followed by a 1-year extension study (Haak et al., 2013).
Results demonstrated lower mean standard deviation (SD) reductions
in HbA1c levels in patients who continued to receive linagliptin 2.5 mg
plus metformin 500 mg twice a day (bid) or 1000 mg bid than with
metformin 1000 mg bid alone, with a low risk of hypoglycemia (Haak
et al., 2013) (Table 1). In treatment-naïve T2DM patients with baseline
HbA1c ≥9.5%, initial therapy with linagliptin plus metformin showed
marked improvements in adjusted mean standard error (SE) changes
from baseline in HbA1c after 24 weeks (−2.8% ± 0.1%) versus
linagliptin monotherapy (−2.0% ± 0.1%) (treatment difference,−0.8%
[95% CI−1.1,−0.50]; P b 0.0001) (Ross et al., 2015).
The initial combination of alogliptin andmetformin (12.5 mg/500 mg
or 12.5 mg/1000 mg bid) provided signiﬁcantly greater reductions in
HbA1c levels from baseline to week 26 versus metformin 500 and
1000 mgbid (Table 1) (Pratley et al., 2014). In addition, the efﬁcacy of the
initial combination of alogliptin 25 mg and pioglitazone 30 mg on β-cell
function and glycemic control was evaluated in patients with T2DM
(N = 71) (Van Raalte et al., 2014). After 16 weeks, mean (SD)
improvements in HbA1c were signiﬁcantly greater with combination
therapy (−0.9% ± 0.1%) than with alogliptin monotherapy (−0.4% ±
0.2%; P b 0.001) or placebo (0.4% ± 0.1%; P b 0.001). The combination of
a DPP-4 inhibitor and TZD also improved β-cell glucose sensitivity versus
placebo, supporting the concept of combination therapy to address
multiple pathophysiological defects.
Unlike in the aforementioned studies of metformin-based oral
combination, treatment-naïve patients were randomized to dual-
inhibitor combination therapy (SGLT2/DPP-4) of empagliﬂozin
25 mg/linagliptin 5 mg, or empagliﬂozin 10 mg/linagliptin 5 mg, or
monotherapy with empagliﬂozin 25 mg, empagliﬂozin 10 mg, or
linagliptin 5 mg (Lewin et al., 2015). After 24 weeks, reductions in
HbA1c were signiﬁcantly greater for empagliﬂozin 25 mg/linagliptin
5 mg versus linagliptin 5 mg (−1.08% vs. –0.67%; P b 0.001), but not
versus empagliﬂozin 25 mg (−0.95%; P = 0.179), and were signif-
icantly greater for empagliﬂozin 10 mg/linagliptin 5 mg versus the
individual components (−1.24% vs. –0.83% and−0.67%, respectively;
P b 0.001 for both). Efﬁcacy was maintained over 52 weeks. Modest
reductions in systolic blood pressure from baseline were observed
with empagliﬂozin/linagliptin combination therapies and empagli-
ﬂozin alone at week 52, but these changes were not signiﬁcantly
different between the combination therapies and their individual
components. In conclusion, initial combination therapy studies
provide evidence of improved glycemic control but lack evidence
regarding long-term macrovascular and microvascular outcomes.
4.2. Macrovascular andmicrovascular outcomeswithnewer T2DMtherapies
in patients with long-standing diabetes
The Saxagliptin Assessment of Vascular Outcomes Recorded in
Patients with Diabetes Mellitus–Thrombolysis in Myocardial
Table 1
Effects of early combination therapy with newer agentsa versus metformin monotherapy in patients with T2DM [adapted from (Phung et al., 2014)].
Study (nb) Follow-up,
weeks
Treatment HbA1c Hypoglycemia
overall (n/N)
Baseline, mean ± SD nc Change, mean (%)
(Bosi, Dotta, Jia, & Goodman, 2009)
(n = 879)
24 Vildagliptin and metformin 100/2000 mg/day 8.7 ± 1.0 285 −1.8 ± 1.01 0/295
Vildagliptin and metformin 100/1000 mg/day 8.6 ± 1.0 277 –1.6 ± 1.0 0/290
Metformin 2000 mg/day 8.6 ± 0.9 285 –1.4 ± 1.01 1/294
(Williams-Herman et al., 2009)
(n = 554)
54 Sitagliptin and metformin 100/1000 mg/day 8.8 ± 1.0 147 −1.4 ± 0.93 4/190
Sitagliptin and metformin 100/2000 mg/day 8.7 ± 0.9 153 −1.8 ± 0.95 5/182
Metformin 2000 mg/day 8.5 ± 0.8 134 −1.3 ± 0.89 2/182
(Olansky et al., 2011) (n = 1246) 44 Sitagliptin and metformin 100/2000 mg/day 9.9 ± 1.8 560 −2.3 ± 1.81 19/625
Metformin 2000 mg/day 9.8 ± 1.8 569 −1.8 ± 1.82 23/621
(Pfützner et al., 2011) (n = 971) 76 Saxagliptin and metformin 5/2000 mg/day 9.4 ± 1.2 303 −2.3 ± 1.22 15/320
Saxagliptin and metformin 10/2000 mg/day 9.5 ± 1.2 313 −2.3 ± 1.24 22/323
Metformin 2000 mg/d 9.4 ± 1.3 308 −1.8 ± 1.23 20/308
(Henry et al., 2012) Study 1 (n = 395) 24 Dapagliﬂozin and metformin XR 5/2000 mg/day 9.2 ± 1.3 185 −2.1 ± 1.21 5/194
Metformin XR 2000 mg/day 9.1 ± 1.2 195 −1.4 ± 1.25 0/201
(Henry et al., 2012) Study 2 (n = 419) 24 Dapagliﬂozin and metformin XR 10/2000 mg/day 9.1 ± 1.3 211 −2.0 ± 1.11 7/211
Metformin XR 2000 mg/day 9.0 ± 1.3 203 −1.4 ± 1.09 6/208
(Haak et al., 2012) (n = 577) 24 Linagliptin and metformin 5/1000 mg/day 8.7 ± 1.0 137 −1.2 ± 0.1 5/143
Linagliptin and metformin 5/2000 mg/day 8.7 ± 1.0 140 −1.6 ± 0.1 0/143
Metformin 1000 mg/day 8.7 ± 0.9 141 −0.6 ± 0.1 2/144
Metformin 2000 mg/day 8.5 ± 0.9 138 −1.1 ± 0.1 5/147
(Haak et al., 2013) (n = 566) 52 Linagliptin and metformin 5/1000 mg/day 8.6 ± 0.9d 113d −1.3 ± 1.1.d 0.4%
Linagliptin and metformin 5/2000 mg/day 8.6 ± 1.0d 111d −1.6 ± 1.1d 0%
Metformin 2000 mg/day 8.5 ± 0.9d 109d −1.3 ± 0.9d 0%
(Pratley, Fleck, & Wilson, 2014) (n = 450) 26 Alogliptin and metformin 25/1000 mg/day 8.50e NR −1.2 ± 0.09e 2/106
Alogliptin and metformin 25/2000 mg/day 8.43e −1.6 ± 0.09e 6/114
Metformin 1000 mg/day 8.50e −0.7 ± 0.09e 2/109
Metformin 2000 mg/day 8.39e −1.1 ± 0.09e 7/111
(Rosenstock et al., 2016) (n = 711) 26 Canagliﬂozin and metformin XR 100/2000 mg/dayf 8.8 ± 1.1 235 −1.8 ± 0.07e 10/237
Canagliﬂozin and metformin XR 300/2000 mg/dayf 8.9 ± 1.2 236 −1.8 ± 0.07e 13/237
Metformin XR 2000 mg/dayf 8.8 ± 1.2 230 −1.3 ± 0.07e 11/237
HbA1c, glycated hemoglobin; XR, extended release; NR, not reported.
Adapted from Phung et al., (2014) Diabetes, Obesity and Metabolism with permission © 2013 John Wiley & Sons Ltd.
a Excludes studies with sulfonylureas, glinides, and thiazolidinediones that are included in Phung et al. meta-analysis; includes additional recent studies not discussed in Phung et al.
(2014) meta-analysis.
b Randomized to shown metformin and combination therapy groups only; excludes DPP-4 inhibitor only group.
c May be less than total sample size due to attrition.
d Non-switched patients only (i.e., those who had continued taking the same trial medication from the previous trial Haak et al., 2012; changes were analyzed from the baseline
visit of the 6-month trial to the end of the 52-week extension for a total of 1.5 years.
e Standard deviation NR for baseline values in Pratley et al. (2014); changes from baseline reported as mean ± standard error in Pratley et al. (2014) and Rosenstock et al. (2016).
f Metformin XR was titrated to maximum dosage of 2000 mg/day.
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of Cardiovascular Outcomes with Alogliptin versus Standard of Care
(EXAMINE) (White et al., 2013) trials were the ﬁrst prospective
studies of a DPP-4 inhibitor or placebo added to standard of care
completed in accordance with FDA guidance regarding exclusion of
unacceptable CVD risk. Subsequently, the results of the Trial
Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS)
(Green et al., 2015), the Evaluation of Cardiovascular Outcomes in
Patients with Type 2 Diabetes after Acute Coronary Syndrome During
Treatment with Lixisenatide (ELIXA) (Pfeffer et al., 2015), and the
Empagliﬂozin Cardiovascular Outcome Event Trial in Type 2 Diabetes
Mellitus Patients (EMPA-REG OUTCOME) were reported (Zinman
et al., 2015).
The SAVOR-TIMI 53 trial (N = 16,492) assessed CV outcomeswith
saxagliptin treatment added to existing glucose-lowering and CV
therapy in patients with a history or heightened risk of CV events
(Table 2) (Scirica et al., 2013). Saxagliptin treatment (median
2.1 years) plus standard care did not increase the risk of the primary
MACE endpoints (HR, 1.00 [95% CI 0.89, 1.12]; P b 0.001 for
non-inferiority; P = 0.99 for superiority) versus placebo. However,
saxagliptin did increase the risk of hospitalization for HF (HR, 1.27
[95% CI 1.07, 1.51]; P = 0.007) versus placebo (Scirica et al., 2013,
2014). Patients with prior HF and estimated glomerular ﬁltration rate
≤60 mL/min and/or increased N-terminal-pro-B-type natriuretic
peptide levels at baseline were at greater risk of HF (Scirica et al.,
2014). In a subsequent analysis, saxagliptin reduced progressive
albuminuria (Udell et al., 2015).The EXAMINE trial (White et al., 2013) (N = 5380) assessed
MACE with alogliptin added to existing diabetes and CV therapy in
patients with a recent history of ACS. Alogliptin treatment (median
18 months) did not increase the risk of MACE versus placebo (HR,
0.96 [95% CI upper boundary, 1.16]; P b 0.001 for non-inferiority;
P = 0.32 for superiority). A post hoc analysis of the EXAMINE trial
revealed that alogliptin did not signiﬁcantly increase the risk of the
ﬁrst hospitalization occurrence for HF (HR, 1.07 [95% CI 0.79, 1.46];
P = 0.657) (Zannad et al., 2015).
TECOS (N = 14,671) assessed CV outcomes with sitagliptin or
placebo added to an existing CV and diabetes regimen for a median
3 years (Green et al., 2015). For the primary composite CV outcome,
sitagliptin was non-inferior to placebo (HR, 0.98 [95% CI 0.88, 1.09];
P b 0.001). In contrast to SAVOR-TIMI 53, the risk of hospitalization
for HF did not differ signiﬁcantly between sitagliptin and placebo (HR,
1.00 [95% CI 0.83, 1.20]; P = 0.98).
The results of the trials mentioned in this section demonstrate
similar composite CV outcomes among patients with T2DM treated
with DPP-4 inhibitors or placebo plus usual care, supporting CV safety
of this class among patients with a high risk for CVD. The risk of
hospitalization for HF was heterogeneous among these three CV
outcomes trials, perhaps because of differences in patient enrollment
and background care provided, variations in how HF was deﬁned,
pharmacologic differences among DPP-4 inhibitors (Green et al.,
2015), or differences in the length of follow-up or the level of HF
severity in each study. Data from these trials suggest that increased
risk of hospitalization for HF is not a class effect of DPP-4 inhibitors.
Table 2
Baseline characteristics and key clinical outcomes of cardiovascular outcomes trials in patients with long-standing T2DM and increased CV risk.
Characteristic or
outcome
SAVORTIMI (Mosenzonet al.,
2013; Scirica et al., 2013)
EXAMINE (White et al.,
2013; Zannad et al., 2015)
TECOS (Green et al., 2015) ELIXA (Bentley-Lewis et al.,
2015; Pfeffer et al., 2015)
EMPA-REG OUTCOME (Zinman
et al., 2014; Zinman et al., 2015)
Saxagliptin
(N = 8280)
Placebo
(N = 8212)
Alogliptin
(N = 2701)
Placebo
(N = 2679)
Sitagliptin
(N = 7332)
Placebo
(N = 7339)
Lixisenatide
(N = 3034)
Placebo
(N = 3034)
Empagliﬂozin
(N = 4687)
Placebo
(N = 2333)
Median follow-up (y) 2.1 1.5 3.0 2.1 3.1
Mean diabetes duration (y)a 10.3 10.3 7.1 7.3 11.6 11.6 9.2 9.4 N10 y, 57% N10 y, 57%
Mean baseline HbA1c(% ± SD) 8.0 ± 1.4 8.0 ± 1.4 8.0 ± 1.1 8.0 ± 1.1 7.2 ± 0.5 7.2 ± 0.5 7.7 ± 1.3 7.6 ± 1.3 8.1 ± 0.8 8.1 ± 0.9
Established CVD (%)b 78.4 78.7 100 100 73.6 74.5 100 100 99 99
Background therapy (%)c
Metformin 70 69 65 67 81 82 67 65 74 74
Sulfonylurea 41 40 47 46 46 45 33 34 43 43
Insulin 42 41 29 30 24 23 39 39 48 49
Primary MACE
deﬁnition
CV death, nonfatal MI, or
nonfatal ischemic stroke
CV death, nonfatal
MI, nonfatal stroke
CV death, nonfatal MI,
nonfatal stroke, or UA
hospitalization
CV death, nonfatal MI,
nonfatal stroke, or UA
hospitalization
CV death, nonfatal MI,
or nonfatal stroke
Primary MACE, HR (95% CI) 1.00 (0.89 to 1.12) 0.96 (1.16d) 0.98 (0.88 to 1.09) 1.02 (0.89 to 1.17) 0.86 (0.74 to 0.99f)
P value (non-inferiority) b0.001 b0.001 b0.001 0.001 b0.001
P value (superiority) 0.99 0.32 0.65e 0.81 0.04
HF hospitalization, HR (95% CI) 1.27 (1.07 to 1.51) 1.07 (0.79 to 1.46) 1.00 (0.83 to 1.20) 0.96 (0.75 to 1.23) 0.65 (0.50 to 0.85)
P value 0.007 0.657 0.98 0.75 0.002
CABG, coronary artery bypass graft; CAD, coronary artery disease; CI, conﬁdence interval; CV, cardiovascular; ELIXA, Evaluation of LIXisenatide in Acute Coronary Syndrome;
EXAMINE: Examination of Cardiovascular Outcomes: Alogliptin versus Standard Care in Patients with Type 2 Diabetes and Acute Coronary Syndrome; HbA1c, glycated hemoglobin;
HF, heart failure; HR, hazard ratio; MACE, major adverse cardiovascular event; MI, myocardial infarction; PCI, percutaneous coronary intervention; SAVOR-TIMI-53: Saxagliptin
Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus–Thrombolysis in Myocardial Infarction; T2DM, type 2 diabetes mellitus; TECOS, Trial Evaluating
Cardiovascular Outcomes with Sitagliptin; UA, unstable angina.
a Median duration, SAVOR TIMI and EXAMINE; mean duration, TECOS and ELIXA.
b SAVOR TIMI: established atherosclerotic disease; EXAMINE and ELIXA: acute coronary syndrome; TECOS: prior CV disease (MI, ≥50% coronary stenosis, prior PCI, CABG);
EMPA-REG OUTCOME: CAD, single-vessel CAD, or multi-vessel CAD; history of MI; CABG; history of stroke; peripheral artery disease; cardiac failure.
c Thiazolidinediones in ≤6.2% of patients.
d Upper boundary of the 1-sided repeated CI.
e HR for the intention-to-treat analysis, 0.98 (0.89–1.08).
f 95.02% CI.
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statement, which was published before the results of the TECOS trial,
this class of drugs “should probably be used cautiously, if at all, in
patients with pre-existing heart failure” (Inzucchi et al., 2015).
TheELIXA trial (N = 6068) is theﬁrst to report the safety andefﬁcacy
of a glucagon-like peptide-1 (GLP-1) receptor agonist in a patient
population with T2DM and a recent ACS event (Bentley-Lewis et al.,
2015). After 2.1 years (median), lixisenatidewas non-inferior to placebo
for the primary CV composite (HR, 1.02 [95% CI 0.89, 1.17]; P = 0.81)
(Sanoﬁ, 2015). Risks of hospitalization for HF were similar for both
groups (HR, 0.96 [95%CI 0.75, 1.23]; P = 0.75).When combinedwith the
evidence from the three DPP-4 inhibitor trials, the data support a neutral
effect of incretin-based therapy on composite MACE.
Finally, EMPA-REG OUTCOME is the ﬁrst CV outcomes trial to
report a decreased risk of MACE and CV mortality with a glucose-
lowering agent, speciﬁcally the SGLT2 inhibitor empagliﬂozin, in
patients with T2DM and high CV risk (Zinman et al., 2014). Overall,
7020 patients received treatment with empagliﬂozin 10 mg or 25 mg
or placebo once daily (plus standard of care) for amedian of 2.6 years;
the median observation period was 3.1 years. Signiﬁcantly fewer
patients in the pooled empagliﬂozin versus placebo group (10.5% vs.
12.1%) experienced the primary composite outcome (HR, 0.86 [95.02%
CI 0.74, 0.99]; P b 0.001 for non-inferiority; P = 0.04 for superiority)
(Fig. 1A) (Zinman et al., 2015). The authors indicated that the
reduction in CV death drove the difference between treatments for the
primary outcome; empagliﬂozin treatment provided a 38% RR
reduction in death from CV causes (HR, 0.62 [95% CI 0.49, 0.77];
P b 0.001). However, no signiﬁcant between-group differences in the
rates of nonfatal MI or stroke were observed. The key secondary
composite endpoint (4-point MACE, including hospitalization for
unstable angina) met the test for non-inferiority (HR, 0.89 [95% CI
0.78, 1.01]; P b 0.001), but empagliﬂozin was not superior to placebofor this outcome (P = 0.08). Also, empagliﬂozin treatment versus
placebo signiﬁcantly reduced all-cause mortality (5.7% and 8.3%,
respectively; 32% RR reduction) (Fig. 1B). The absolute risk reduction
in all-causemortality was 2.6%, thus, to prevent one death, 39 patients
need to be treated for 3 years. Although not a component of the
primary or key secondary endpoints, empagliﬂozin treatment
provided a 35% RR reduction in the rate of hospitalization for HF
(HR, 0.65 [95% CI 0.50, 0.85]; P = 0.002) (Fitchett et al., 2016).
4.3. Multifactorial therapy
The Steno-2 study evaluated multifactorial therapy with intensive
antihyperglycemic therapy, antihypertensives, aspirin, and lipid-
lowering agents in patients with T2DM and microalbuminuria
(Gaede, Lund-Andersen, Parving, & Pedersen, 2008; Gaede, Vedel,
Parving, & Pedersen, 1999; Gaede et al., 2003). Patients had a mean
HbA1c of 8.4%–8.8% and median disease duration of 5.5–6.0 years
(Gaede et al., 1999). During the ﬁrst 3.8 years of follow-up, intensive
versus conventional therapy reduced the risk of nephropathy (odds
ratio [OR], 0.27 [95% CI 0.10, 0.75]; P = 0.01), retinopathy (OR, 0.45
[95% CI 0.21, 0.95]; P = 0.04), and autonomic neuropathy (OR, 0.31
[95% CI 0.12, 0.78]; P = 0.01) (Gaede et al., 1999). Reductions were
maintained after a mean 7.8 years of additional follow-up (nephrop-
athy HR, 0.39 [95% CI 0.17, 0.87]; P = 0.003 and retinopathy HR, 0.42
[95% CI 0.21, 0.86]; P = 0.02). After 7.8 years, intensive therapy
decreased the risk of the primary composite macrovascular endpoint
(unadjusted HR 0.47 [95% CI 0.24, 0.74]; P = 0.008) (Gaede et al.,
2003). After a mean follow-up of 17 years, the original intensive-
therapy group had an absolute risk reduction of 2.8% for composite CV
endpoints (Gaede et al., 2008). The authors concluded that the use of
statins and antihypertensive drugs may have had the largest effect on
long-term CV risk.
Fig. 1. Primary MACE outcome and death from any cause in the EMPA-REG outcome
trial. The ﬁgures show the cumulative incidence of the primary MACE outcome (death
from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke) (A), and
the cumulative incidence of the Kaplan–Meier estimate for death from any cause (B)
and in the pooled empagliﬂozin group and the placebo group among patients who
received at least one dose of a study drug. Hazard ratios are based on Cox regression
analyses. From The New England Journal of Medicine, Zinman G, et al., Empagliﬂozin,
Cardiovascular Outcomes, and Mortality in Type 2 Diabetes, Volume 373, page 2117–
22. Copyright © 2015 Massachusetts Medical Society. Reprinted with permission from
Massachusetts Medical Society.
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therapy during the early stages of diabetes, the Anglo-Danish-Dutch
Study of Intensive Treatment in People with Screen Detected Diabetes
in Primary Care (ADDITION) (Charles et al., 2011; Grifﬁn et al., 2011)
trials were conducted. Drawing from three different countries, the
ADDITION-Europe study randomized patients with T2DM to intensive
multifactorial or conventional therapy, and assessed primary CV
endpoints and non-traumatic amputation for a mean of 5.3 years.
Patients had amean HbA1c of 7.0% and N90% had a history of CV events
(Grifﬁn et al., 2011). Intensive management over a 5-year period was
associated with a modest improvement in HbA1c, cholesterol, and
blood pressure and a non-signiﬁcant 17% relative reduction in the
incidence of composite CV endpoints (HR 0.83 [95% CI 0.65, 1.05];
P = 0.12) versus conventional therapy. The ADDITION-Denmark
study screened 1533 patients for T2DM and randomized them to
intensive or conventional therapy, followed by 6 years of observation
for diabetic peripheral neuropathy (DPN) or peripheral artery disease
(PAD) (Charles et al., 2011). Baseline HbA1c was 6.4%. Intensive
treatment did not change the incidence of DPN or PAD. The authors
postulated that an extended period of intensive therapy was required
to observe a clinically signiﬁcant effect on DPN or PAD even with early
treatment initiation.5. The future: ongoing long-term outcome trials
Multiple clinical trials, which are underway or recently completed,
are evaluating the addition of newer classes of glucose-loweringagents to the standard of care and are assessing macrovascular
outcomes, microvascular outcomes, or both.
5.1. GLP-1 receptor agonists
The clinical trials EXSCEL (NCT01144338), REWIND (NCT01394952),
LEADER (NCT01179048), and SUSTAIN 6 (NCT01720446) are evaluating
the impact of exenatide once-weekly, dulaglutide, liraglutide, and
semaglutide, respectively, on CV and/or microvascular outcomes in
patients with T2DM.
5.2. DPP-4 inhibitors
Two trials of DPP-4 inhibitor therapy are ongoing in patients with
T2DM and CVD or high CV risk. The CAROLINA (Rosenstock et al., 2013)
trial includes patients with early T2DM and directly compares linagliptin
to an active comparator, glimepiride, primarilywhenadded tometformin.
The CARMELINA (NCT01897532) trial will examine CV and renal
microvascular outcomes of linagliptin in high-risk individualswith T2DM.
5.3. SGLT2 inhibitors
The clinical trials DECLARE-TIMI 58 (NCT01730534) and CANVAS
(Neal et al., 2013) are evaluating the impact of dapagliﬂozin and
canagliﬂozin, respectively, in patients with T2DM and high risk of CV
complications. Two other ongoing trials are primarily designed to
assess renal outcomes with canagliﬂozin use − the CANVAS-R
(NCT01989754) trial, with the change in albuminuria as the primary
outcome, and the CREDENCE (NCT02065791) trial, which will
evaluate treatment in patients with diabetic nephropathy.
5.4. TZD and SUs
In the PROactive trial (Section 3.2), pioglitazone signiﬁcantly
reduced the risk of the composite secondary endpoint (Dormandy
et al., 2005). Patients were on a wide range of glucose-lowering
medications, including insulin. In contrast, a comparison of add-on
pioglitazone versus add-on SU in high CV-risk patients inadequately
controlled with metformin is underway in the TOSCA.IT trial (Vaccaro
et al., 2012). In the ﬁnal analysis, which is expected in 2018, both CV
and microvascular endpoints will be considered after at least
48 months of treatment (Vaccaro et al., 2012).
5.5. Comparative effectiveness
Selecting the appropriate combination from an armamentarium of
glucose-lowering drugs can be challenging for physicians. Although
T2DM algorithms recommend various treatment combinations, few
studies have directly compared these combinations. The Glycemia
Reduction Approaches in Diabetes: A Comparative Effectiveness
(GRADE) study is an ongoing comprehensive examination of four
classes of glucose-lowering drugs (SUs, DPP-4 inhibitors, GLP-1
receptor agonists, and insulin) in addition to metformin (Nathan
et al., 2013). GRADE will compare the long-term effectiveness of each
drug combinationwith respect to glycemic control over time, CVD risk
factors, and microvascular complications in 5000 patients recently
diagnosed with T2DM (duration b5 years), and will also evaluate the
phenotypic differences that contribute to the efﬁcacy and safety of
each combination. The results of this study will help guide physicians
in establishing individualized regimens for their patients.
6. Conclusion
Based on current knowledge, providing combination therapy in
the form of metformin with one additional agent as soon as possible
after diagnosis results in improved glycemic control (Phung et al.,
1183S. Milligan / Journal of Diabetes and Its Complications 30 (2016) 1177–11852014). Whether initial combination therapy improves long-term
outcomes compared with a more traditional stepwise approach
remains unknown. Indeed, early-onset pathophysiologic damage
induced by hyperglycemia and worsening metabolic control, a
consequence of this progressive disease, substantiates the use of
early combination therapy.
The current clinical trial evidence includes a number of combina-
tion therapies in patients with long-standing diabetes, and permits
assessment of the effect of intensive glycemic control on microvas-
cular and macrovascular outcomes. Evidence from ADVANCE (Patel
et al., 2008; Zoungas et al., 2014) and VADT (Duckworth et al., 2009)
indicate long-term beneﬁts of intensive glycemic control on micro-
vascular outcomes. However, these two studies and ACCORD
(Gerstein et al., 2008) found no signiﬁcant reduction in the risk of
macrovascular outcomes with intensive versus standard glycemic
control within the ﬁrst 3.5–5.6 years of follow-up. Interestingly,
improvements in CV outcomes became apparent after an additional
~5 years in ACCORD (Gerstein et al., 2014) and ~10 years in VADT
(Hayward et al., 2015), similar to the ﬁndings of the UKPDS (Holman
et al., 2008), but not after 6 years of follow-up in ADVANCE (Zoungas
et al., 2014). These differences may reﬂect heterogeneity among
the trials.
The recent CV outcome trials, EXAMINE (White et al., 2013),
SAVOR-TIMI 53 (Scirica et al., 2013, 2014; Udell et al., 2015), and
TECOS (Green et al., 2015) were primarily designed to examine CV
safety, and included patients who already had a CV event or were at
high risk of CVD. Although SAVOR-TIMI 53 and TECOS enrolled a
sufﬁcient number of patients for a superiority analysis, improvements
in CV outcomes remained elusive. Possible explanations include short
treatment duration (≤3 years) and a populationwith long-standing or
advanced disease, thus, the intervention may have been too late. In
contrast, the EMPA-REG OUTCOME trial was the ﬁrst trial of a
glucose-lowering agent plus standard of care to show a reduction in
CV risk in a population with T2DM and existing CVD (Zinman et al.,
2015). A reduction in the rate of CV and all-cause death occurred early
and was maintained for the duration of the trial. Further investigation
is needed to elucidate the mechanism(s) underlying the mortality
beneﬁts of empagliﬂozin. Non-glycemic effects of empagliﬂozin,
including changes in arterial stiffness, cardiac function, cardiac
oxygen demand (in the absence of sympathetic-nerve activation),
cardio–renal effects, reductions in albuminuria and uric acid, and
effects on weight, visceral adiposity, and blood pressure have been
proposed (Zinman et al., 2015).
Support for improvement in microvascular and macrovascular
outcomes with early, aggressive therapy is conﬂicting. UKPDS
(Holman et al., 2008) supports the use of intensive therapy to
improve long-term microvascular and macrovascular outcomes,
although signiﬁcant improvements in MI and death from any cause
did not materialize until 10 years post-trial. The ORIGIN (Gerstein
et al., 2012) trial was the ﬁrst key evaluation of long-term CV
outcomes in patients with T2DM. Participants had IFG, IGT, or newly
diagnosed T2DM, but insulin glargine therapy targeting near-normal
FPG levels did not signiﬁcantly reduce the risk of macrovascular
outcomes. The ADDITION (Charles et al., 2011; Grifﬁn et al., 2011) trial
used a unique strategy to assess CV and microvascular outcomes with
multifactorial early intervention in a population with screen-detected
diabetes. Conﬂicting results of the ADDITION (Charles et al., 2011;
Grifﬁn et al., 2011) studies are similar to previous studies of the
impact of intensive glycemic control on the incidence of diabetic
neuropathy (UKPDS, ACCORD, and Steno-2) (Gaede et al., 2008;
Ismail-Beigi et al., 2010; UKPDS Group, 1998).
The rationale for early combination treatment in adults with T2DM
is straightforward, and studies clearly support a glycemic beneﬁt.
However, evidence of long-term improvements in macrovascular
outcomes with early combination therapy is limited. Early intensive
combination therapy may be a way to offset early pathophysiologicdamage resulting from hyperglycemia, therefore reducing the period
in which patients are exposed to hyperglycemia.
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